PT972020E - Peptidos agonistas do factor den crescimento tipo insulina - Google Patents

Peptidos agonistas do factor den crescimento tipo insulina

Info

Publication number
PT972020E
PT972020E PT98915236T PT98915236T PT972020E PT 972020 E PT972020 E PT 972020E PT 98915236 T PT98915236 T PT 98915236T PT 98915236 T PT98915236 T PT 98915236T PT 972020 E PT972020 E PT 972020E
Authority
PT
Portugal
Prior art keywords
den
factor agonist
agonist peptides
type growth
insulin type
Prior art date
Application number
PT98915236T
Other languages
English (en)
Inventor
Henry B Lowman
Iain C A F Robinson
Ross G Clark
Original Assignee
Genentech Inc
Robinson Iain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Robinson Iain filed Critical Genentech Inc
Publication of PT972020E publication Critical patent/PT972020E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
PT98915236T 1997-04-04 1998-03-31 Peptidos agonistas do factor den crescimento tipo insulina PT972020E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/825,852 US6121416A (en) 1997-04-04 1997-04-04 Insulin-like growth factor agonist molecules

Publications (1)

Publication Number Publication Date
PT972020E true PT972020E (pt) 2003-02-28

Family

ID=25245064

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98915236T PT972020E (pt) 1997-04-04 1998-03-31 Peptidos agonistas do factor den crescimento tipo insulina

Country Status (13)

Country Link
US (16) US6121416A (pt)
EP (2) EP0972020B1 (pt)
JP (1) JP4562814B2 (pt)
AT (1) ATE224951T1 (pt)
AU (1) AU732989B2 (pt)
CA (1) CA2286264A1 (pt)
DE (1) DE69808258T2 (pt)
DK (1) DK0972020T3 (pt)
ES (1) ES2183344T3 (pt)
HK (1) HK1047755A1 (pt)
IL (1) IL131925A0 (pt)
PT (1) PT972020E (pt)
WO (1) WO1998045427A2 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US20030224017A1 (en) * 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
CA2389575A1 (en) * 1999-10-29 2001-05-10 Oregon Health Sciences University Modulation of neuroendocrine differentiation by protein 25.1
WO2001072323A2 (en) 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
FR2810675B1 (fr) * 2000-06-22 2002-09-27 Pf Medicament Construction modifiee en aval du codon d'initiation pour la surexpression de proteines recombinantes
DE60143858D1 (de) * 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6790672B2 (en) * 2001-02-19 2004-09-14 Board Of Regents The University Of Texas System Encoded molecular sieve particle-based sensors
EP1401476A4 (en) 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
AU2002363800A1 (en) * 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US7118877B2 (en) * 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
JP4719465B2 (ja) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー．ブイ． インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US7279971B2 (en) * 2002-09-06 2007-10-09 Telefonaktiebolaget Lm Ericsson (Publ) Composite power amplifier
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
AU2003297259A1 (en) * 2002-11-14 2004-06-03 Wyeth Methods and compositions for treating neurological disorders
US7273788B2 (en) * 2003-05-21 2007-09-25 Micron Technology, Inc. Ultra-thin semiconductors bonded on glass substrates
PL1636593T3 (pl) * 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
JP2007537711A (ja) * 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド Ｉｇｆ結合タンパク質
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
EA010803B1 (ru) * 2004-03-19 2008-12-30 Мерк Патент Гмбх Модифицированные белки буганины, цитотоксины и способы их применения
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
WO2006138315A2 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
JP5290148B2 (ja) 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
JP2010536880A (ja) * 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
WO2009105709A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
MX2013004315A (es) 2010-10-20 2013-07-17 Genentech Inc Metodos y composiciones para modular la ruta wnt.
BR112014008863A2 (pt) 2011-10-14 2019-08-20 Genentech Inc peptídeo ativador de zimogene (zap) isolado, fusão de zap, métodos
CN103974709B (zh) 2011-10-14 2016-12-14 霍夫曼-拉罗奇有限公司 Bace1的肽抑制剂
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
EA202090705A1 (ru) 2017-09-11 2020-06-11 Шайр Хьюман Дженетик Терапиз, Инк. Способы и композиции, предназначенные для лечения хронических заболеваний легких
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method
CA3194764A1 (en) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
DE102021122096A1 (de) 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
CN117347626B (zh) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 人胰岛素样生长因子结合蛋白-1化学发光免疫分析试剂盒及其制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
PH23185A (en) 1983-06-13 1989-05-29 Scheindel Ass Inc Pressure operated dispensing container
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
EP0134094B1 (en) 1983-08-15 1987-05-27 AMP INCORPORATED (a New Jersey corporation) An improved compliant section for circuit board contact elements
US5077276A (en) * 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
JP2648951B2 (ja) * 1987-04-06 1997-09-03 セルトリックス ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
ES2007309T3 (es) * 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) * 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) * 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ES2330052T3 (es) * 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
EP0686040A1 (en) * 1993-01-29 1995-12-13 Amgen Boulder Inc. Wound healing composition
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5854211A (en) * 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1995017423A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
BRPI9608799B8 (pt) * 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
EP1961760A3 (en) * 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
PL185040B1 (pl) * 1995-06-07 2003-02-28 Affymax Tech Nv Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
EP0854884A1 (en) * 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
DE59705394D1 (de) 1996-04-25 2001-12-20 Storz Karl Gmbh & Co Kg Chirurgisches instrumentensystem
CA2276049A1 (en) 1996-12-27 1998-07-09 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Also Published As

Publication number Publication date
ATE224951T1 (de) 2002-10-15
US6635619B1 (en) 2003-10-21
CA2286264A1 (en) 1998-10-15
US6693078B1 (en) 2004-02-17
AU732989B2 (en) 2001-05-03
WO1998045427A2 (en) 1998-10-15
US6632794B1 (en) 2003-10-14
EP0972020B1 (en) 2002-09-25
IL131925A0 (en) 2001-03-19
JP2002510194A (ja) 2002-04-02
DE69808258D1 (de) 2002-10-31
US6645775B1 (en) 2003-11-11
US6683053B1 (en) 2004-01-27
ES2183344T3 (es) 2003-03-16
JP4562814B2 (ja) 2010-10-13
AU6947098A (en) 1998-10-30
US6677305B1 (en) 2004-01-13
US6620789B1 (en) 2003-09-16
US6949349B1 (en) 2005-09-27
US6689751B1 (en) 2004-02-10
DK0972020T3 (da) 2003-02-03
EP0972020A1 (en) 2000-01-19
DE69808258T2 (de) 2003-09-18
WO1998045427A3 (en) 1999-01-07
US6716586B1 (en) 2004-04-06
EP1251137A3 (en) 2003-04-16
US6713451B1 (en) 2004-03-30
US6680298B1 (en) 2004-01-20
HK1047755A1 (zh) 2003-03-07
US6608031B1 (en) 2003-08-19
EP1251137A2 (en) 2002-10-23
US6121416A (en) 2000-09-19
US6693079B1 (en) 2004-02-17
US6251865B1 (en) 2001-06-26

Similar Documents

Publication Publication Date Title
PT972020E (pt) Peptidos agonistas do factor den crescimento tipo insulina
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
IL95118A0 (en) Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
CA2381219A1 (en) Monomeric protein of the tgf-beta family
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
ATE395938T1 (de) Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung
DK1282437T3 (da) Behandling af brusklidelser
DE69334146D1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
FI972170A (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
ATE245998T1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
DK1073623T3 (da) Substituerede aminosyrer som erythropoietin-mimetika
DE68905097T2 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
DE69534596D1 (de) Epil/plazentin
DE50011068D1 (de) Fragmente des virus proteins 2 oder 3 des polyomavirus als fähren für wirkstoffe
ES2147519B1 (es) Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
MX9702475A (es) Analogos del factor de crecimiento acido de fibroblasto que tienen estabilidad y acticidad biologica mejoradas.